Stock Events

Stock Events

Ultragenyx Pharmaceutical 

$15.85
52
-$0.25-1.55%Wednesday 07:53

Statistics

Day High
15.87
Day Low
15.27
52W High
36.75
52W Low
14.45
Volume
131
Avg. Volume
-
Mkt Cap
1.56B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 3Expected
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Q3 2026
-1.84
-1.53
-1.21
-0.9
Expected EPS
-1.100396
Actual EPS
-1.16

Financials

-85.44%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
673MRevenue
-575MNet Income

Analyst Ratings

$26.18Average Price Target
The highest estimate is ⁦40.00⁩.
From 18 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RARE.BOATS. It's not an investment recommendation.
Amazon
12
AMZN
NVIDIA
12
NVDA
Apple
11
AAPL
Microsoft
10
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Ultragenyx's focus on rare genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical competes directly with Ultragenyx in the rare disease space, particularly in developing enzyme replacement therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in developing treatments for rare diseases among other areas, making it a competitor.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk is a leading company in diabetes care but also ventures into treatments for rare blood disorders, competing with Ultragenyx.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, known for its work in antiviral drugs, also has a portfolio in other areas including rare diseases, making it a competitor.
AMGEN
AMGN
Mkt Cap251.94B
Amgen has a broad focus on biologics in various therapeutic areas, including rare diseases, competing with Ultragenyx in this niche.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a diversified portfolio that includes treatments for rare diseases, making it a competitor to Ultragenyx.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurological diseases, including some rare conditions, positioning it as a competitor in the rare disease market.

About

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Show More
CEO
ISIN
US90400D1081

Listings

STU
DE
UP0.STU
SA
BR
R2AR34.SA
LSE
GB
0LIF.LSE
F
DE
UP0.F

0 Comments

Share your thoughts

FAQs

What is Ultragenyx Pharmaceutical stock price today?▼
The current price of RARE.BOATS is $15.85 USD — it has decreased by -1.55% in the past 24 hours. Watch Ultragenyx Pharmaceutical stock price performance more closely on the chart.
What is Ultragenyx Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Ultragenyx Pharmaceutical stocks are traded under the ticker RARE.BOATS.
What is Ultragenyx Pharmaceutical market cap?▼
Today Ultragenyx Pharmaceutical has the market capitalization of 1.56B
When is the next Ultragenyx Pharmaceutical earnings date?▼
Ultragenyx Pharmaceutical is going to release the next earnings report on February 18, 2027.
What were Ultragenyx Pharmaceutical earnings last quarter?▼
RARE.BOATS earnings for the last quarter are -1.16 USD per share, whereas the estimation was -1.1 USD resulting in a -5.42% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ultragenyx Pharmaceutical revenue for the last year?▼
Ultragenyx Pharmaceutical revenue for the last year amounts to 673M USD.
What is Ultragenyx Pharmaceutical net income for the last year?▼
RARE.BOATS net income for the last year is -575M USD.
In which sector is Ultragenyx Pharmaceutical located?▼
Ultragenyx Pharmaceutical operates in the Other sector.
When did Ultragenyx Pharmaceutical complete a stock split?▼
Ultragenyx Pharmaceutical has not had any recent stock splits.